Sarcoma  >>  Tasigna (nilotinib)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tasigna (nilotinib) / Novartis, Inhibikase
NCT01735955 / 2012-003902-28: Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Completed
4
57
Europe, Canada, US, RoW
Nilotinib, AMN107
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
07/23
07/23
NCT00756509 / 2008-000358-11: Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Active, not recruiting
4
34
Europe
Nilotinib
Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
12/24
12/24

Download Options